Atherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease
(CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with …

Aims Chronic limb-threatening ischaemia (CLTI) entails dismal outcomes and is an absolute
indication to lower extremity revascularization (LER) whenever possible. Antithrombotic …

Lower-limb peripheral arterial disease (PAD), is a common manifestation of systemic
atherosclerosis, resulting from a partial or complete obstruction of at least one lower-limb …

Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with
coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the …

Background: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5 mg
rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to ASA …

Despite available effective guideline-based preventive therapies, patients with vascular
diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are …

Aims Patients with coronary and peripheral artery disease (PAD) have a residual risk of
major adverse cardiovascular and limb events despite standards of care. Among patients …

The evidence for beta-blocker therapy after myocardial infarction (MI) is from randomized
trials conducted more than 30 years ago, and its continued efficacy has been questioned. 1 …

Randomized controlled trials (RCTs) have demonstrated the superiority of a strategy of
patent foramen ovale (PFO) percutaneous closure associated with antiplatelet therapy over …

Choroba układu sercowo-naczyniowego o podłożu miażdżycy (ASCVD, atherosclerotic
cardiovascular disease), która obejmuje chorobę wieńcową (CAD, coronary artery disease) …